Trial Profile
A Randomized, Placebo-Controlled Study to Evaluate the Effect of Tafenoquine (SB252263) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Tafenoquine (Primary) ; Moxifloxacin
- Indications Babesiosis; Malaria; Pneumocystis pneumonia
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 10 Sep 2018 Results published in the Antimicrobial Agents and Chemotherapy
- 12 Apr 2014 New trial record